CTRI/2024/05/068070尚未招募3 期
A Randomized, Placebo-Controlled, Double-Blind Clinical Study to evaluate the Efficacy and Safety of a Dose for Soreness (Dietary supplement) in reducing Muscle Soreness and improving muscle relaxation in Healthy adults - Nil
Eetho Brands0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female subjects between 19 to 60 years of age
- •2. Adult subjects with good health, as determined by a health history and at the Investigators discretion.
- •3. Subject willing to participate and able to comply with the protocol.
- •4. Subjects who provide written, signed, and dated informed consent.
排除标准
- •1. Subjects with a sleep disorder or a history of clinical depression, eating disorders, or other psychiatric conditions.
- •2. Subjects with a history or current presence of health conditions, including abnormal resting ECG, bleeding disorder, diabetes, high blood pressure, thyroid disease, tachyarrhythmia, heart disease, kidney disease, or liver disease.
- •3. Participants using medications - anti-inflammatory, analgesic, antioxidant drugs, nutritional products, and dietary supplements that may interfere with the study results, as determined by the investigators opinion.
- •4. History of allergy or sensitivity to any ingredient in the test product, as well as a history of alcohol or other drug abuse within the last year.
- •5. Participation in another clinical study within the past 30 days.
- •6. Subjects with a history of orthopaedic injury or surgery within the last year.
- •7. Presence of any physical condition considered a contraindication to the type of exercise to be performed in the study.
- •8. Subjects who do not agree to participate or are not capable of complying with protocol requirements.
- •9. Women who are pregnant or breastfeeding.
研究者
相似试验
进行中(未招募)
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseMedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2016-004599-23-ITGENKYOTEX SA111
进行中(未招募)
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphatasePrimary Biliary CholangitisEUCTR2016-004599-23-GBGenkyotex SA102
进行中(未招募)
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseMedDRA version: 20.0 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000023866Primary Biliary CholangitisEUCTR2016-004599-23-GRGenkyotex SA102
招募中
2 期
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacyand Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis ReceivingUrsodeoxycholic Acid and with Persistently Elevated Alkaline PhosphatasePrimary Biliary CholangitsK74.3Primary biliary cirrhosisDRKS00013664Genkyotex SA102
进行中(未招募)
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseMedDRA version: 20.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000023866Primary Biliary CholangitisEUCTR2016-004599-23-ESGenkyotex SA102
